Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H18N4O3S2.CH4O3S |
| Molecular Weight | 498.596 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CN(C(=O)CC1=CC=C(C=C1)C2=NC=CC=C2)C3=NC(C)=C(S3)S(N)(=O)=O
InChI
InChIKey=PPAJHCGEURRDOG-UHFFFAOYSA-N
InChI=1S/C18H18N4O3S2.CH4O3S/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15;1-5(2,3)4/h3-10H,11H2,1-2H3,(H2,19,24,25);1H3,(H,2,3,4)
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H18N4O3S2 |
| Molecular Weight | 402.491 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pritelivir is a thiazolylamide derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). In preclinical Pritelivir was shown to be active when treatment was delayed to 72 h post viral inoculation and appeared to synergistically inhibit mortality in this model in combination with acyclovir. Pritelivir could be an alternative therapeutic agent for patients infected with acyclovir-resistant strains. Phase II clinical trials currently are ongoing.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. | 2002 Apr |
|
| Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. | 2002 Jun |
|
| ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. | 2010 Aug |
|
| Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir. | 2013 Nov |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:56:53 GMT 2023
by
admin
on
Sat Dec 16 18:56:53 GMT 2023
|
| Record UNII |
UQ8YD6U328
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1428333-96-3
Created by
admin on Sat Dec 16 18:56:53 GMT 2023 , Edited by admin on Sat Dec 16 18:56:53 GMT 2023
|
PRIMARY | |||
|
UQ8YD6U328
Created by
admin on Sat Dec 16 18:56:53 GMT 2023 , Edited by admin on Sat Dec 16 18:56:53 GMT 2023
|
PRIMARY | |||
|
300000048292
Created by
admin on Sat Dec 16 18:56:53 GMT 2023 , Edited by admin on Sat Dec 16 18:56:53 GMT 2023
|
PRIMARY | |||
|
11950374
Created by
admin on Sat Dec 16 18:56:53 GMT 2023 , Edited by admin on Sat Dec 16 18:56:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|